taurine has been researched along with Malignant Melanoma in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and tolerability of taurolidine, an antibacterial substance, was evaluated in a phase 2 trial enrolling patients with advanced melanoma." | 9.15 | The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. ( Baumann, K; Dummer, R; French, LE; Goldinger, SM; Imhof, L; Röthlisberger, P; Schad, K, 2011) |
| " In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells." | 7.76 | Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. ( Kim, AK; Yu, JS, 2010) |
| "This study evaluates whether taurolidine, a novel antibiotic agent, induces murine melanoma cell apoptosis in vitro and in vivo." | 7.74 | Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. ( Gong, SL; Liu, LL; Redmond, HP; Sun, BS; Wang, JH, 2007) |
| "The efficacy and tolerability of taurolidine, an antibacterial substance, was evaluated in a phase 2 trial enrolling patients with advanced melanoma." | 5.15 | The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. ( Baumann, K; Dummer, R; French, LE; Goldinger, SM; Imhof, L; Röthlisberger, P; Schad, K, 2011) |
| " In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells." | 3.76 | Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. ( Kim, AK; Yu, JS, 2010) |
| "This study evaluates whether taurolidine, a novel antibiotic agent, induces murine melanoma cell apoptosis in vitro and in vivo." | 3.74 | Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. ( Gong, SL; Liu, LL; Redmond, HP; Sun, BS; Wang, JH, 2007) |
| "In human donor samples (4 melanoma-affected eyes, and 14 control eyes; age range, 62-93 years), radiochemical techniques were used to determine the RPE taurine accumulation at various exogenous concentrations." | 3.72 | Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina. ( Cunningham, JR; Hillenkamp, J; Hussain, AA; Jackson, TL; Marshall, J, 2004) |
| "Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine." | 3.67 | Phase II study of tauromustine in disseminated malignant melanoma. ( Bergh, J; Blomquist, E; Gjedde, SB; Lindegaard-Madsen, E; Mouridsen, HT; Nolte, H, 1989) |
| "The antitumor activity of 2-[bis-(2-chloroethyl)-amino]ethanesulfonic acid (also referred to here as "taurine mustard" or "taumustine") was evaluated in the murine P388 and L1210 lymphocytic leukemias and in the pigmented and nonpigmented B16 melanoma systems." | 3.67 | Modulation by taurine of the toxicity of taumustine, a compound with antitumor activity. ( Fisher, JM; Pierson, HF; Rabinovitz, M, 1985) |
| "Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, JS | 1 |
| Kim, AK | 1 |
| Imhof, L | 1 |
| Goldinger, SM | 1 |
| Baumann, K | 1 |
| Schad, K | 1 |
| French, LE | 1 |
| Röthlisberger, P | 1 |
| Dummer, R | 1 |
| Shrayer, DP | 1 |
| Lukoff, H | 1 |
| King, T | 1 |
| Calabresi, P | 1 |
| Hillenkamp, J | 1 |
| Hussain, AA | 1 |
| Jackson, TL | 1 |
| Cunningham, JR | 1 |
| Marshall, J | 1 |
| Sun, BS | 1 |
| Wang, JH | 1 |
| Liu, LL | 1 |
| Gong, SL | 1 |
| Redmond, HP | 1 |
| Braumann, C | 1 |
| Jacobi, CA | 1 |
| Rogalla, S | 1 |
| Menenakos, C | 1 |
| Fuehrer, K | 1 |
| Trefzer, U | 1 |
| Hofmann, M | 1 |
| Gjedde, SB | 3 |
| Mouridsen, HT | 3 |
| L-Madsen, E | 2 |
| Jensen, NV | 2 |
| Blomquist, E | 3 |
| Bergh, J | 3 |
| Söderberg, M | 2 |
| Wählby, S | 2 |
| Wheeler, MD | 1 |
| Ikejema, K | 1 |
| Enomoto, N | 1 |
| Stacklewitz, RF | 1 |
| Seabra, V | 1 |
| Zhong, Z | 1 |
| Yin, M | 1 |
| Schemmer, P | 1 |
| Rose, ML | 1 |
| Rusyn, I | 1 |
| Bradford, B | 1 |
| Thurman, RG | 1 |
| Glover, DJ | 1 |
| Nolte, H | 1 |
| Lindegaard-Madsen, E | 1 |
| Smyth, JF | 1 |
| Gundersen, S | 1 |
| Renard, J | 1 |
| Pinedo, HM | 1 |
| Pierson, HF | 1 |
| Fisher, JM | 1 |
| Rabinovitz, M | 1 |
| Vester, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
| Glycine | 109.7 | 133.9 | 115.3 |
| Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |
|---|---|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
| Glycine | 104.1 | 111.8 |
| Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
| Glycine | 105.2 | 105.2 | 115.5 |
| Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
| Glycine | 82.0 | 75.6 | 77.7 |
| Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
1 review available for taurine and Malignant Melanoma
| Article | Year |
|---|---|
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
4 trials available for taurine and Malignant Melanoma
| Article | Year |
|---|---|
The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study.
Topics: Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase II study of tauromustine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compoun | 1994 |
Phase I study of tauromustine administered in a weekly schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Huma | 1993 |
Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Ni | 1989 |
9 other studies available for taurine and Malignant Melanoma
| Article | Year |
|---|---|
Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells.
Topics: Animals; Cell Line, Tumor; Dicarboxylic Acids; Drug Combinations; Humans; Melanins; Melanocytes; Mel | 2010 |
The effect of Taurolidine on adherent and floating subpopulations of melanoma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Drug Screening Assays, Antitumor; Humans; Mel | 2003 |
Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina.
Topics: Aged; Aged, 80 and over; Aging; Binding, Competitive; Biological Transport; Carrier Proteins; Case-C | 2004 |
Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Survi | 2007 |
The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
Topics: Animals; Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Female; Injections, I | 2007 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 1991 |
Phase II study of tauromustine in disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitr | 1989 |
Modulation by taurine of the toxicity of taumustine, a compound with antitumor activity.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Female; Leukemia L1210; Leukemia P388; Male; Melano | 1985 |
Amino acid pattern and malignant growth.
Topics: Amino Acids; Animals; Antineoplastic Agents; Arginine; Fishes; Histones; In Vitro Techniques; Melano | 1965 |